Oncology Pipeline

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

Selective ER Degrader

Imlunestrant

Gladden AB and Diehl JA¹; Patel HK and Bihani T²; Tecalco-Cruz AC, et al³; Wardell SE, et al⁴

Target

Estrogen signaling plays an important role in organ development and growth. In certain cancers, abnormal estrogen signaling via the estrogen receptor is a key component of tumor growth.⁵ Disruption of estrogen signaling by selective estrogen receptor degraders (SERDs) is one of the treatment options for patients with estrogen-receptor-positive (ER+) cancers.

Molecule

Imlunestrant is an orally available SERD that has demonstrated the inhibition of estrogen signaling and subsequent inhibition of cell proliferation in ER-expressing tumor models.

Clinical Development

Imlunestrant is being investigated in clinical trials in patients with ER+ breast cancer or endometrial cancer.

References

Gladden AB, Diehl JA. J Cell Biochem. 2005;96(5):906-913.
Patel HK, Bihani T. Pharmacol Ther. 2018;186:1-24.
Tecalco-Cruz AC, et al. Cell Signal. 2017;34:121-132.
Wardell SE, et al. Clin Cancer Res. 2015;21(22):5121-5130.
Lee HR, et al. Int J Mol Med. 2012;29:883-890.

Need additional information or have a question:

Medical Science Liaison Request

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

View All Trials For This Molecule

DISCOVER OTHER MOLECULES

CDK4 & 6 Inhibitor

Learn More

CDK4 & 6 Inhibitor

Learn More

VEGF Receptor-2 Antagonist

Learn More